^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DSP502
i
Other names: DSP502, DSP-FC 502, DSP 502, DSP FC 502, DSP-502, DSPFC502
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Kahr Medical
Drug class:
PD-L1 inhibitor, TIGIT inhibitor
Related drugs:
10d
DSP502 combines dual inhibition of PD-L1 and PVR to trigger anti-cancer immune responses. (PubMed, Mol Cancer Ther)
Finally, DSP502 inhibited tumor growth by potentiating antitumor immunity in xenograft ovarian and lung cancer models. Collectively, these findings demonstrate that DSP502, by blocking PVR and PD-L1 pathways, has dual ICI activity and holds potential therapeutic benefits for cancers such as NSCLC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule)
|
PD-L1 expression
|
DSP502
over4years
DSP502 — A Novel Approach For Targeting TIGIT And PD1 Pathways For Cancer Immunotherapy (SITC 2021)
Beyond targeting PVR and PDL1, DSP502 has the potential to additionally impact the TIGIT pathway through its effects on CD96 and DNAM1. DSP502 is currently in IND-enabling studies and CMC development.
PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • GZMB (Granzyme B)
|
PD-L1 overexpression
|
DSP502
Share via
